Healthcare | July 05, 2022
Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries
Medicines, including insulin, to be available in 40 lower-income countries
Medicines, including insulin, to be available in 40 lower-income countries
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
It´s the first trial to demonstrate the benefits of dual pathway inhibition
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Subscribe To Our Newsletter & Stay Updated
